Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer von Smyth, Lillian M., Piha-Paul, Sarina A., Won, Helen H., Schram, Alison M., Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I., Juric, Dejan, Mayer, Ingrid A., Arteaga, Carlos L., de la Fuente, Macarena I., Brufksy, Adam M., Spanggaard, Iben, Mau-Sorensen, Morten, Arnedos, Monica, Moreno, Victor, Boni, Valentina, Sohn, Joohyuk, Schwartzberg, Lee S., Gonzalez-Farre, Xavier, Cervantes, Andres, Bidard, Francois-Clement, Gorelick, Alexander N., Lanman, Richard B., Nagy, Rebecca J., Ulaner, Gary A., Chandarlapaty, Sarat, Jhaveri, Komal, Gavrila, Elena I., Zimel, Catherine, Selcuklu, S. Duygu, Melcer, Myra, Samoila, Aliaksandra, Cai, Yanyan, Scaltriti, Maurizio, Mann, Grace, Xu, Feng, Eli, Lisa D., Dujka, Melanie, Lalani, Alshad S., Bryce, Richard, Baselga, Jose, Taylor, Barry S., Solit, David B., Meric-Bernstam, Funda, Hyman, David M.

Volltext

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer von Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M, Waters, Simon H, Hurvitz, Sara A, Moy, Beverly, Kim, Sung-Bae, Gradishar, William J, Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J, Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S, Bryce, Richard, Vivancos, Ana, Eli, Lisa D, Delaloge, Suzette

Volltext

Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer von Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M., Waters, Simon H., Hurvitz, Sara A., Moy, Beverly, Kim, Sung-Bae, Gradishar, William J., Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J., Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S., Bryce, Richard, Vivancos, Ana, Eli, Lisa D., Delaloge, Suzette

Volltext

Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer von Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M, Waters, Simon H, Hurvitz, Sara A, Moy, Beverly, Kim, Sung-Bae, Gradishar, William J, Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J, Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S, Bryce, Richard, Vivancos, Ana, Eli, Lisa D, Delaloge, Suzette

Volltext

Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer von Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M., Waters, Simon H., Hurvitz, Sara A., Moy, Beverly, Kim, Sung-Bae, Gradishar, William J., Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J., Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S., Bryce, Richard, Vivancos, Ana, Eli, Lisa D., Delaloge, Suzette

Volltext